Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
Yu
G
G
Discovery Chemistry, Drug Metabolism and Pharmacokinetics, Drug Safety, and Metabolic & Cardiovascular Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, USA. guixue.yu@bms.com
Mason
H J
HJ
Wu
X
X
Wang
J
J
Chong
S
S
Dorough
G
G
Henwood
A
A
Pongrac
R
R
Seliger
L
L
He
B
B
Normandin
D
D
Adam
L
L
Krupinski
J
J
Macor
J E
JE
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000284:Administration, Oral; D000818:Animals; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D004285:Dogs; D007172:Erectile Dysfunction / Q000188:drug therapy; D066298:In Vitro Techniques; D008297:Male; D009126:Muscle Relaxation / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D010413:Penis / Q000187:drug effects / Q000502:physiology; D010726:Phosphodiesterase Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D011725:Pyridines / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D013329:Structure-Activity Relationship
D010726:Phosphodiesterase Inhibitors; D011725:Pyridines; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517384:Pde5a protein, rat